World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://wjon.elmerpub.com

Original Article

Volume 16, Number 4, August 2025, pages 342-346

Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital

Tables

↓  Table 1. Summary of Cohort Characteristics
 
Cohort characteristic (n = 14) N (%)
BMI: body mass index.
Age at diagnosis
  Median 28.5
  Range 21 - 57
  21 - 39 (young adults) 12 (85.7)
  40 - 57 (adult) 2 (14.3)
Biologic sex
  Male 5 (35.7)
  Female 9 (64.3)
BMI
  Median 31.4
  Range 21.8 - 49.0
  18.5 - 24.9 1 (7.1)
  25 - 29.9 4 (28.6)
  30 - 39.9 5 (5.7)
  ≥ 40 4 (28.6)
Ethnicity
  Hispanic 14 (100)
Philadelphia chromosome
  Positive 2 (14.3)
  Negative 12 (85.7)

 

↓  Table 2. Lab Values Obtained at Diagnosis Compared to Their Peak Values
 
Lab parameter At diagnosis At peak value
ALT: alanine aminotransferase; AST: aspartate aminotransferase; IQR: interquartile range.
ALT
  Median (IQR) 54 (32, 107) 453 (218, 643)
  Range 15 - 191 43 - 3491
AST
  Median (IQR) 48 (38, 63) 325 (216, 468)
  Range 22 - 175 51 - 3137
Total bilirubin
  Median (IQR) 0.9 (0.7, 1.2) 3.3 (2.8, 13.7)
  Range 0.4 - 11.4 1.2 - 32.3

 

↓  Table 3. Frequency of Adverse Events in Our Cohort
 
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
N (%) N (%) N (%) N (%) N (%)
All grades were assessed using CTCAE version 5.0 definitions. If a grade is not applicable to a particular adverse event, it is reported as “-”. CTCAE: Common Terminology Criteria for Adverse Events.
Allergic reaction/hypersensitivity 1 (7%) 0 0 0 0
Hyperbilirubinemia 2 (14%) 5 (36%) 1 (7%) 5 (36%) 0
Hypertriglyceridemia 1 (7%) 2 (14%) 1 (7%) 0 0
Pancreatitis - 1 (7%) 0 0 0
Thrombosis 0 6 (43%) 0 0 0
Transaminitis (ALT) 1 (7%) 1 (7%) 10 (71%) 2 (14%) 0
Transaminitis (AST) 1 (7%) 2 (14%) 9 (64%) 2 (14%) 0